Article Sidebar
Views Online First: 30
EFFECTIVENESS OF KENU TM CAPSULES IN SUPPORTING LIPID-LOWERING TREATMENT IN PATIENTS WITH HYPERCHOLESTEROLEMIA
Main Article Content
Abstract
Aims: To evaluate the effectiveness of Kenu TM capsules in supporting lipid-lowering treatment of in patients with hypercholesterolemia.
Methods: A randomized open-label clinical trial was conducted on 487 patients with hypercholesterolemia. The subjects were divided into two groups, high cardiovascular risk group, and low cardiovascular risk group, according to the American Heart Association and American College of Cardiology 2018 recommendations. In each group, the subjects were randomly assigned to the intervention and control groups. The intervention group used Kenu TM capsules for three months.
Results: After three months, plasma cholesterol concentration decreased more in the intervention group than that in the control group (low cardiovascular risk and high cardiovascular risk group: 0.9 ± 1.4 versus -0.1 ±1.9; 0.9 ± 1.4 versus 0.1 ± 1.0 mmol/L, respectively), p < 0.05. Kenu TM capsules were effective in reducing the number of patients with hypercholesterolemia by 1.7 times with RR (95%CI): 1.7 (1.1-2.5) in the low cardiovascular risk group and 2.6 times with RR (95%CI): 2.6 (1.6-4.3) in the high cardiovascular risk group compared with the control group. After 3 months, plasma triglyceride concentration decreased more in the intervention group than that in the control group (low cardiovascular risk and high cardiovascular risk group: 1.2 ± 2.4 versus -0.8 ± 2.5; 1.5 ± 3.2 versus -0.7 ± 3.2 mmol/L, respectively) with p < 0.05.
Conclusion: Kenu TM capsules could have had the effect of reducing plasma cholesterol, and triglyceride in patients with hypercholesterolemia after three months.
Article Details
Keywords
Hypercholesterolemia, 𝘓𝘢𝘤𝘵𝘰𝘣𝘢𝘤𝘪𝘭𝘶𝘴 𝘱𝘭𝘢𝘯𝘵𝘢𝘳𝘶𝘮
References
2. Bui TV, Blizzard CL, Luong KN, et al. National survey of risk factors for non-communicable disease in Vietnam: prevalence estimates and an assessment of their validity. BMC Public Health. 2016;16. doi:10.1186/s12889-016-3160-4
3. Grundy Scott M., Stone Neil J., Bailey Alison L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003
4. Kiessling G, Schneider J, Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr. 2002;56(9):843-849. doi:10.1038/sj.ejcn.1601399
5. Fuentes MC, Lajo T, Carrión JM, Cuñé J. A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol. Mediterr J Nutr Metab. 2016;9(2):125-135. doi:10.3233/MNM-160065
6. Rerksuppaphol S, Rerksuppaphol L. A Randomized Double-blind Controlled Trial of Lactobacillus acidophilus Plus Bifidobacterium bifidum versus Placebo in Patients with Hypercholesterolemia. J Clin Diagn Res JCDR. 2015;9(3):KC01-04. doi:10.7860/JCDR/2015/11867.5728
7. Ml J, Cj M, S P. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012;66(11). doi:10.1038/ejcn.2012.126
8. Hidalgo NJ, Pando E, Alberti P, et al. The role of high serum triglyceride levels on pancreatic necrosis development and related complications. BMC Gastroenterol. 2023;23(1):51. doi:10.1186/s12876-023-02684-9
9. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and Cardiovascular Disease. Circulation. 2011;123(20):2292-2333. doi:10.1161/CIR.0b013e3182160726
10. Mikelsaar M, Sepp E, Štšepetova J, et al. Regulation of plasma lipid profile by lactobacillus fermentum (probiotic strain ME-3 DSM14241) in a randomised controlled trial of clinically healthy adults. BMC Nutr. 2015;1(1):27. doi:10.1186/s40795-015-0020-z.